Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes o...
Saved in:
Main Authors: | Jieun Kang, Jin Woo Song |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/98744e44e4c2472da78b957c76dcc9cc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
by: Yuzo Suzuki, et al.
Published: (2021) -
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
by: Ho Cheol Kim, et al.
Published: (2021) -
Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice
by: Jooae Choe, et al.
Published: (2021) -
A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis
by: Myung Jin Song, et al.
Published: (2021) -
Functional Wnt signaling is increased in idiopathic pulmonary fibrosis.
by: Melanie Königshoff, et al.
Published: (2008)